David T. Rubin, MD

Correlation Between Histologic Indices and Ulcerative Colitis Activity Measures Among Patients in the HICKORY (Etrolizumab) Open-Label Induction Cohort

BACKGROUND: Cross-sectional studies in ulcerative colitis (UC) have shown at best a moderate association between histologic and clinical measures of disease activity, but few longitudinal...

Brian G. Feagan ;

David T. Rubin , MD;

Rish Pai ;

Audrey Boruvka ;

Young Oh ;

Alexis Scherl ;

Astrid Scalori ;

Pablo Arrisi ;

Laurent Peyrin-Biroulet ;

Swati Tole ;

12/13/2019

P028 Communicating Needs and Features of IBD Experiences (CONFIDE) Survey: Patient and Healthcare Professional Perspectives on Experience of Ulcerative Colitis Symptoms

BACKGROUND: Moderate-to-severe ulcerative colitis (UC) and Crohn’s disease (CD) are associated with substantial quality of life and economic burdens (Kawalec, 2016). The Commu...

Theresa Hunter Gibble ;

Remo Panaccione ;

Alison Potts Bleakman ;

Cem Kayhan ;

David T. Rubin , MD;

Christian Atkinson ;

Hilary Ellis ;

Kristine Healey ;

Mingyang Shan ;

Toshifumi Hibi ;

12/15/2021

Using Wearable Devices to Predict Length of Stay For IBD Patients After Bowel Surgery

BACKGROUND: Understanding the factors that contribute to a prolonged length of stay (LOS) for IBD patients after bowel surgery is essential to improving the quality of care provided to th...

David T. Rubin , MD;

Yangtian Yi ;

Philip Sossenheimer ;

Victoria Rai ;

Katia El Jurdi ;

12/13/2019

Incorporation of a Screening Program for Mental Health in Inflammatory Bowel Disease Identifies Many Patients With Undiagnosed or Ineffectively Treated Anxiety and Depression

University of Chicago Medicine Inflammatory Bowel Disease Center, Chicago, Illinois, United States.

David T. Rubin , MD;

Natalie K. Choi ;

Alexandra McDermott ;

Emma A. Picker ;

Alyse Bedell ;

Adar Zinger ;

01/11/2024

Extraintestinal Manifestations at Baseline, and Effect of Tofacitinib in Patients With Moderate to Severe Ulcerative Colitis in the OCTAVE Program

BACKGROUND: Extraintestinal manifestations (EIMs) occur in approximately one-third of patients with ulcerative colitis (UC) (1). Tofacitinib is an oral, small molecule JAK inhibitor for t...

Paulo Gustavo Kotze ;

David T. Rubin , MD;

Marcia Pinheiro ;

Gary R. Lichtenstein ;

Haiyun Fan ;

Walter Reinisch ;

Marc Fellmann ;

Irene Modesto ;

Nervin Lawendy ;

Eric Maller ;

Thomas Greuter ;

Stephen Vavricka ;

12/12/2019

Intestinal Ultrasound in Severe Ulcerative Colitis Treated With Intravenous Cyclosporine

1 University of Chicago, Chicago, Illinois, United States; 2 University of Chicago Medicine Inflammatory Bowel Disease Center, Chicago, Illinois, United States.

Noa Krugliak Cleveland ;

David T. Rubin , MD;

Emma A. Picker ;

Yusuke Miyatani ;

Jeremy Klein ;

01/11/2024

Factors Predicting Compliance With Passive and Active Monitoring in Inflammatory Bowel Disease Patients

BACKGROUND: Updated goals of management of IBD patients include monitoring disease activity, yet compliance with such strategies is poorly studied. We are performing a multi-year study of...

David T. Rubin , MD;

Yangtian Yi ;

Philip Sossenheimer ;

Victoria Rai ;

Jorie Singer ;

Jordan Karpin ;

Tina Rodriguez ;

Olivia Yvellez ;

12/12/2019

Efficacy and Safety of Icanbelimod (CBP-307) in Adults With Moderate to Severe Ulcerative Colitis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial

1 Peking Union Medical College Hospital, Chinese Academy of Medical Science, Peking Union Medical College, Beijing, China; 2 The Affiliated Hospital of Qingdao University, Qingdao, Qingda...

Feng Xu ;

Jiaming Qian ;

Zibin Tian ;

Yanqing Li ;

Fangyu Wang ;

Xiaolan Zhang ;

Hong Yang ;

David T. Rubin , MD;

Jiawang Guo ;

Wubin Pan ;

Brian G. Feagan ;

Raul Collazo ;

Zheng Wei ;

Guang-dan Zhu ;

Silvio Danese ;

01/11/2024

Podcasts

IBD Drive Time: Streamlining the Prior Authorization Process

12/14/2023

David T. Rubin , MD;

Dr David Rubin discusses the hurdles of prior authorization and ways to manage the process to ensure patients can receive their IBD therapies with guests David Choi, PharmD, and Mona Shah, MPH.

Dr David Rubin discusses the...

12/14/2023

Pharmacy Learning Network